Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin's lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a detectable tumor. The effusion contains tumor cells universally infected with human herpesvirus 8 (HHV8), which is the critical factor differentiating PEL from HHV8-unrelated PEL-like lymphoma (PEL-LL). This report describes a 77-year-old male patient with pleural effusion and ascites, containing lymphoma cells expressing a B-cell phenotype, but without markers of HHV8 in immunocytochemical analysis. The patient was diagnosed with PEL-LL and treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. The patient is currently disease-free 15 months post-treatment. To the best of our knowledge, this is the first report on administration of R-CHOP in a PEL-LL patient in South Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Junghoon
J
Shin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Jeong-Ok
JO
Lee
Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Ji-Young
JY
Choe
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Soo-Mee
SM
Bang
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Jong-Seok
JS
Lee
D000367:Age Factors; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D001706:Biopsy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006566:Herpesviridae Infections / Q000150:complications*; D019288:Herpesvirus 8, Human; D006801:Humans; D054685:Lymphoma, Primary Effusion / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D064847:Multimodal Imaging / Q000379:methods; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Human herpesvirus 8; Primary effusion lymphoma; R-CHOP protocol